Group: antituberculosis agent
Tablet 150 mg + 100 mg, 300 mg + 150 mg

General information

A fixed combination of rifampicin and isoniazid has been developed as an aid to compliance. It is essential that all such products are shown to have adequate bioavailability.

Clinical information

Uses

Both drugs are components of all 6- and 8-month antituberculosis chemotherapeutic regimens currently recommended by WHO (see pages 12 and 13).

Dosage and administration

Adults:

> 50 kg: 2 tablets (300 mg rifampicin + 150 mg isoniazid) daily.
< 50 kg: 3 tablets (150 mg rifampicin + 100 mg isoniazid) daily.

The combination tablets are not suitable for paediatric use.

For contraindications, precautions, use in pregnancy, adverse effects and drug interactions, see information given for the separate components.

Storage

Tablets should be stored in tightly closed containers.